The preventive effect on respiratory tract infections of Oscillococcinum®. A cost-effectiveness analysis by Colombo GL, Di Matteo S, Martinotti C, Oselin M, Bruno GM, Beghi GM

Connect to this object online.

Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study by Torre E, Bruno GM, Di Matteo S, Martinotti C, Valentino MC, Bottaro LC, Colombo GL

Connect to this object online.

Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative by Colombo GL, Di Matteo S, Martinotti C, Jugl SM, Gunda P, Naclerio M, Bruno GM

Connect to this object online.

Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study by Canonica GW, Colombo GL, Rogliani P, Santus P, Pitotti C, Di Matteo S, Martinotti C, Bruno GM

Connect to this object online.

Economic Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Italy. Analysis and Perspectives by Torre E, Di Matteo S, Martinotti C, Bruno GM, Goglia U, Testino G, Rebora A, Bottaro LC, Colombo GL

Connect to this object online.

Economic Burden of Non-Alcoholic Steatohepatitis (NASH) Among Diabetic Population in Italy: Analysis and Perspectives by Torre E, Di Matteo S, Bruno GM, Martinotti C, Valentino MC, Testino G, Rebora A, Bottaro LC, Colombo GL

Connect to this object online.

Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes by Torre E, Bruno GM, Di Matteo S, Martinotti C, Oselin M, Valentino MC, Parodi A, Bottaro LC, Colombo GL

Connect to this object online.

Economic Impact of COVID-19 Lockdown on Italian NHS: Focus on Diabetes Mellitus by Torre E, Colombo GL, Di Matteo S, Martinotti C, Valentino MC, Rebora A, Cecoli F, Monti E, Galimberti M, Di Bartolo P, Gaggioli G, Bruno GM

Connect to this object online.